AntiAsthmatics And COPD Drugs Market Analysis, Size, Trends, Share Estimation, And Forecast To 2032 | Novartis AG, Merck & Co., GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca

Spread the love

The AntiAsthmatics And COPD Drugs Global Market Report 2023 by The Business Research Company, provides anti-asthmatics and copd drugs market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten-year historic period – 2010-2021, and a ten-year forecast period – 2023-2032.

Learn More On The AntiAsthmatics And COPD Drugs Market:

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

According to The Business Research Company’s AntiAsthmatics And COPD Drugs Global Market Report 2023, the market size is expected to grow from $88.20 billion in 2022 to $94.10 billion in 2023 at a compound annual growth rate (CAGR) of 6.7% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global anti-asthmatics and copd drugs is expected to grow to $117.36 billion in 2027 at a CAGR of 5.7% .

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend in smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=3802&type=smp

The anti-asthmatics and copd drugs market is segmented:

1) AntiAsthmatics And COPD Drugs Market By Type: Anti-histamine Drugs, long-acting ß2-agonists (LABA), Inhaled corticosteriods, Short-acting muscarinic receptor antagonists (SAMAs), Other Anti-Asthmatics And COPD Drugs (including Combinations)

2) AntiAsthmatics And COPD Drugs Market By Drug Class: Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, Combination Drugs

3) AntiAsthmatics And COPD Drugs Market By End User: Asthma Patients, COPD Patients

4) AntiAsthmatics And COPD Drugs Market By Distribution Channel: Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, E-Commerce

Top Major Players

Novartis AG

Merck & Co.

GlaxoSmithKline

Boehringer Ingelheim Gmbh

AstraZeneca

Developing the patent expiration of innovator drugs is restricting the anti-asthmatics and COPD drugs market. Due to patent expiration, generic drugs are entering the market which is inexpensive when compared to innovator drugs. For example, the patent for roflumilast tablets expired in January 2020. Daliresp, roflumilast tablets are a prescription medication meant for patients with severe COPD to reduce the number of episodes of COPD. Therefore, developing patent expiration of innovator drugs is expected to hamper the growth of the anti-asthmatics and COPD drugs market in the forecast period.

The anti-asthmatics and copd drugs market report table of contents includes:

1. Executive Summary

2. AntiAsthmatics And COPD Drugs Characteristics

3. AntiAsthmatics And COPD Drugs Market Trends And Strategies

4. AntiAsthmatics And COPD Drugs Market – Macro Economic Scenario

5. AntiAsthmatics And COPD Drugs Market Size And Growth

…..

26. Africa AntiAsthmatics And COPD Drugs Market

27. AntiAsthmatics And COPD Drugs Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The AntiAsthmatics And COPD Drugs Market

29. AntiAsthmatics And COPD Drugs Market Future Outlook and Potential Analysis

30. Appendix